Correlation between tuberous sclerosis complex 2 and glycogen synthase kinase 3 beta levels, and outcomes of patients with hepatocellular carcinoma treated by hepatectomy

Hepatology Research

Volumn 44, Issue 11, 2014, Pages 1142-1150

  Huang, Ka Te ^a   Huang, Yue Han ^a   Li, Peng ^a   He, Bin ^a   Chen, Zhen Kun ^a   Yu, Xia ^a   Chen, Jian Ou ^a   Zhang, Qi Yu ^a   Shi, Hong Qi ^a   Shan, Yun Feng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Expression; Glycogen synthase kinase 3 ; Hepatectomy; Hepatocellular carcinoma; Prognosis; Tuberous sclerosis complex 2

Indexed keywords

ALPHA FETOPROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; TUBERIN;

ADULT; ARTICLE; BILE DUCT; BILE DUCT THROMBOSIS; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; SURVIVAL RATE; THROMBOSIS; TUMOR INVASION; VASCULAR INVASION;

EID: 84914122282     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12256     Document Type: Article

References (36)

1. Zheng LY, Zhou DX, Lu J, Zhang WJ, Zou DJ. Down-regulated expression of the protein-tyrosine phosphatase 1B (PTP1B) is associated with aggressive clinicopathologic features and poor prognosis in hepatocellular carcinoma. Biochem Biophys Res Commun 2012; 420: 680-684.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
3. Chen HC, Jeng YM, Yuan RH, Hsu HC, Chen YL. SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis. Ann Surg Oncol 2012; 19: 2011-2019.
4. Drake JM, Graham NA, Stoyanova T etal. Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression. Proc Natl Acad Sci U S A 2012; 109: 1643-1648.
5. Liu X, Rubin JS, Kimmel AR. Rapid, Wnt-induced changes in GSK3beta associations that regulate beta-catenin stabilization are mediated by Galpha proteins. Curr Biol 2005; 15: 1989-1997.
6. Luo J. Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett 2009; 273: 194-200.
7. Lustig B, Behrens J. The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol 2003; 129: 199-221.
8. Mai W, Kawakami K, Shakoori A etal. Deregulated GSK3{beta} sustains gastrointestinal cancer cells survival by modulating human telomerase reverse transcriptase and telomerase. Clin Cancer Res 2009; 15: 6810-6819.
9. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003; 115: 577-590.
10. Jiang WG, Sampson J, Martin TA etal. Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes. Eur J Cancer 2005; 41: 1628-1636.
11. Chakraborty S, Mohiyuddin SM, Gopinath KS, Kumar A. Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma. BMC Cancer 2008; 8: 163.
12. Inoki K, Ouyang H, Zhu T etal. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 2006; 126: 955-968.
13. Cai XD, Zhou YB, Huang LX etal. Reduced expression of Kruppel-like factor 17 is related to tumor growth and poor prognosis in lung adenocarcinoma. Biochem Biophys Res Commun 2012; 418: 67-73.
14. Radulescu S, Ridgway RA, Cordero J etal. Acute WNT signalling activation perturbs differentiation within the adult stomach and rapidly leads to tumour formation. Oncogene 2013; 32: 2048-2057.
15. Xu X, Sun PL, Li JZ, Jheon S, Lee CT, Chung JH. Aberrant Wnt1/beta-catenin expression is an independent poor prognostic marker of non-small cell lung cancer after surgery. J Thorac Oncol 2011; 6: 716-724.
16. Zhou H, Huang H, Shi J etal. Prognostic value of interleukin 2 and interleukin 15 in peritumoral hepatic tissues for patients with hepatitis B-related hepatocellular carcinoma after curative resection. Gut 2010; 59: 1699-1708.
17. Kriegl L, Jung A, Engel J etal. Expression, cellular distribution, and prognostic relevance of TRAIL receptors in hepatocellular carcinoma. Clin Cancer Res 2010; 16: 5529-5538.
18. Zhao Y, Wang X, Wang T etal. Acetylcholinesterase, a key prognostic predictor for hepatocellular carcinoma, suppresses cell growth and induces chemosensitization. Hepatology 2011; 53: 493-503.
19. Leng S, Zhang W, Zheng Y etal. Glycogen synthase kinase 3 beta mediates high glucose-induced ubiquitination and proteasome degradation of insulin receptor substrate 1. J Endocrinol 2010; 206: 171-181.
20. Thiel A, Heinonen M, Rintahaka J etal. Expression of cyclooxygenase-2 is regulated by glycogen synthase kinase-3beta in gastric cancer cells. J Biol Chem 2006; 281: 4564-4569.
21. Quintayo MA, Munro AF, Thomas J etal. GSK3beta and cyclin D1 expression predicts outcome in early breast cancer patients. Breast Cancer Res Treat 2012; 136: 161-168.
22. Desbois-Mouthon C, Blivet-Van EMJ, Beurel E etal. Dysregulation of glycogen synthase kinase-3beta signaling in hepatocellular carcinoma cells. Hepatology 2002; 36: 1528-1536.
23. Chiang PC, Lin SC, Pan SL etal. Antroquinonol displays anticancer potential against human hepatocellular carcinoma cells: a crucial role of AMPK and mTOR pathways. Biochem Pharmacol 2010; 79: 162-171.
24. Rosner M, Hanneder M, Siegel N, Valli A, Fuchs C, Hengstschlager M. The mTOR pathway and its role in human genetic diseases. Mutat Res 2008; 659: 284-292.
25. Jozwiak J, Jozwiak S, Grzela T, Lazarczyk M. Positive and negative regulation of TSC2 activity and its effects on downstream effectors of the mTOR pathway. Neuromolecular Med 2005; 7: 287-296.
26. Tam KH, Yang ZF, Lau CK, Lam CT, Pang RW, Poon RT. Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma. Cancer Lett 2009; 273: 201-209.
27. Gedaly R, Angulo P, Chen C etal. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment. Anticancer Res 2012; 32: 2531-2536.
28. Kudo M. mTOR inhibitor for the treatment of hepatocellular carcinoma. Dig Dis 2011; 29: 310-315.
29. Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torbenson M. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 2004; 10: 8421-8425.
30. Villanueva A, Chiang DY, Newell P etal. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008; 135: 1972-1983, 1983.e1-11.
31. Budde K, Gaedeke J. Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition. Am J Kidney Dis 2012; 59: 276-283.
32. Jentarra GM, Rice SG, Olfers S, Saffen D, Narayanan V. Evidence for population variation in TSC1 and TSC2 gene expression. BMC Med Genet 2011; 12: 29.
33. van Veelen W, Korsse SE, van de Laar L, Peppelenbosch MP. The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling. Oncogene 2011; 30: 2289-2303.
34. Tomasoni R, Mondino A. The tuberous sclerosis complex: balancing proliferation and survival. Biochem Soc Trans 2011; 39: 466-471.
35. Liu H, Radisky DC, Nelson CM etal. Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2. Proc Natl Acad Sci U S A 2006; 103: 4134-4139.
36. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 2009; 9: 563-575.